Related Experiment Video
Updated: May 29, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Genetic variants in candidate genes influencing NAFLD progression
Michelino Di Rosa1, Lucia Malaguarnera
1Department of Biomedical Sciences, University of Catania, Via Androne, 83, 95124 Catania, Italy.
Journal of Molecular Medicine (Berlin, Germany)
|September 7, 2011
Summary
Genetic variants in nonalcoholic fatty liver disease (NAFLD) are key to understanding disease progression. Identifying these genetic factors may improve patient management for this metabolic disorder.
Area of Science:
- Hepatology and Genetic Research
- Metabolic Disorders
Background:
- Nonalcoholic fatty liver disease (NAFLD) encompasses simple steatosis and nonalcoholic steatohepatitis (NASH).
- Advanced NASH can lead to fibrosis, cirrhosis, and hepatocarcinoma, increasing liver and cardiovascular mortality.
- NASH is linked to the worsening of metabolic syndrome.
Purpose of the Study:
- To critically review recently identified genetic variants in NAFLD patients.
- To identify potential risk factors contributing to NAFLD progression.
- To explore the role of genetic polymorphisms in metabolic dysfunctions.
Main Methods:
- Review of human epidemiologic studies on genetic polymorphisms.
- Analysis of gene variants associated with metabolic dysfunctions in NAFLD.
- Evaluation of altered genotypes and clinical variables.
Main Results:
- Recent studies have identified specific genetic variants in NAFLD patients.
- These variants may act as risk factors influencing disease progression.
- Genetic factors contribute to the understanding of NAFLD's pathophysiologic origins.
Conclusions:
- Genetic variants play a significant role in the development and progression of NAFLD.
- Identifying these genetic factors can aid in risk stratification.
- Integrating genetic data with clinical variables may enhance patient management strategies for NAFLD.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...